Xilio Therapeutics, Inc. Balance Sheet
XLO|2 years of annual SEC 10-K data (FY2024-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 2 fiscal years. All figures from audited SEC 10-K filings.
Xilio Therapeutics, Inc. had $155M in total assets and $18M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.71 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Cash & Equivalents | $137.5M | $55.3M |
| Current Assets | $145.0M | $60.2M |
| PP&E (Net) | $3.9M | $4.5M |
| Total Assets | $154.7M | $71.1M |
| Current Liabilities | $56.3M | $27.3M |
| Shareholders' Equity | $17.6M | $36.8M |